Inhibition of platelet aggregation by combined therapy with aspirin and cilostazol after off-pump coronary artery bypass surgery

Annals of Thoracic and Cardiovascular Surgery

Volumn 14, Issue 4, 2008, Pages 230-237

  Onoda, Koji ^a   Ohashi, Kayoko ^b   Hashimoto, Akira ^b   Okuda, Masahiro ^b   Shimono, Takatsugu ^a   Nishikawa, Masakatsu ^a   Shimpo, Hideto ^a  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b MIE UNIVERSITY HOSPITAL   (Japan)

Author keywords

Antiplatelet drug; Cardiopulmonary bypass; Off pump coronary artery bypass surgery; Platelet aggregation

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CILOSTAZOL; FIBRINOGEN; TETRAZOLE DERIVATIVE; VON WILLEBRAND FACTOR;

AGED; ARTICLE; BLOOD; BLOOD CLOTTING PARAMETERS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; DRUG EFFECT; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; OFF PUMP CORONARY SURGERY; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOSIS; TIME; TREATMENT OUTCOME;

AGED; ASPIRIN; CORONARY ARTERY BYPASS, OFF-PUMP; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOGEN; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; PLATELET FUNCTION TESTS; TETRAZOLES; THROMBOSIS; TIME FACTORS; TREATMENT OUTCOME; VON WILLEBRAND FACTOR;

EID: 54049158152     PISSN: 13411098     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. van Dijk D, Nierich AP, Jansen EW, Nathoe HM, Suyker WJ, et al. Early outcome after off-pump versus on-pump coronary bypass surgery: results from a randomized study. Circulation 2001; 104: 1761-6.
2. Sabik JF, Blackstone EH, Lytle BW, Houghtaling PL, Gillinov AM, et al. Equivalent midterm outcomes after off-pump and on-pump coronary surgery. J Thorac Cardiovasc Surg 2004; 127: 142-8.
3. Puskas JD, Williams WH, Duke PG, Staples JR, Glas KE, et al. Off-pump coronary artery bypass grafting provides complete revascularization with reduced myocardial injury, transfusion requirements, and length of stay: a prospective randomized comparison of two hundred unselected patients undergoing off-pump versus conventional coronary artery bypass grafting. J Thorac Cardiovasc Surg 2003; 125: 797-808.
4. Mariani MA, Gu YJ, Boonstra PW, Grandjean JG, van Oeveren W, et al. Procoagulant activity after offpump coronary operation: is the current anticoagulation adequate? Ann Thorac Surg 1999; 67: 1370-5.
5. Cartier R, Robitaille D. Thrombotic complications in beating heart operations. J Thorac Cardiovasc Surg 2001; 121: 920-2.
6. Kurlansky PA. Is there a hypercoagulable state after off-pump coronary artery bypass surgery? What do we know and what can we do? J Thorac Cardiovasc Surg 2003; 126: 7-10.
7. Quigley RL, Fried DW, Pym J, Highbloom RY. Offpump coronary artery bypass surgery may produce a hypercoagulable patient. Heart Surg Forum 2003; 6: 94-7.
8. Gum PA, Thamilarasan M, Watanabe J, Blackstone EH, Lauer MS. Aspirin use and all-cause mortality among patients being evaluated for known or suspected coronary artery disease: a propensity analysis. JAMA 2001; 286: 1187-94.
9. Gavaghan TP, Gebski V, Baron DW. Immediate postoperativeaspirin improves vein graft patency early and late after coronary artery bypass graft surgery. A placebo-controlled, randomized study. Circulation 1991; 83: 1526-33.
10. D'Ancona G, Donias HW, Karamanoukian RL, Bergsland J, Karamanoukian HL. OPCAB therapy survey: off-pump clopidogrel, aspirin or both therapy survey. Heart Surg Forum 2001; 4: 354-8.
11. Tanaka T, Ishikawa T, Hagiwara M, Onoda K, Itoh H, et al. Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor, on the contraction of vascular smooth muscle. Pharmacology 1988; 36: 313-20.
12. Dawson DL, Cutler BS, Meissner MH, Strandness DE Jr. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation 1998; 98: 678-86.
13. Gotoh F, Tohgi H, Hirai S, Terashi A, Fukuuchi, Y, et al. Cilostazol stroke prevention study: a placebocontrolled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis 2000; 9: 147-57.
14. Tsuchikane E, Fukuhara A, Kobayashi T, Kirino M, Yamasaki K, et al. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty.Circulation 1999; 100: 21-6.
15. Douglas JS Jr, Holmes DR Jr, Kereiakes DJ, Grines CL, Block E, et al. Cilostazol for Restenosis Trial (CREST) Investigators. Coronary stent restenosis in patients treated with cilostazol. Circulation 2005; 112: 2826-32.
16. Tanigawa T, Nishikawa M, Kitai T, Ueda Y, Okinaka T, et al. Increased platelet aggregability in response to shear stress in acute myocardial infarction and its inhibition by combined therapy with aspirin and cilostazol after coronary intervention. Am J Cardio l2000; 85: 1054-9.
17. Wilhite DB, Comerota AJ, Schmieder FA, Throm RC, Gaughan JP, et al. Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time. J Vasc Surg 2003; 38: 710-3.
18. Nishikawa M, Hidaka H. Role of calmodulin in platelet aggregation. Structure-activity relationship of calmodulin antagonists. J Clin Invest 1982; 69: 1348-55.
19. Ikeda Y, Handa M, Kawano K, Kamata T, Murata M,et al. The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress. J Clin Invest 1991; 87: 1234-40.
20. Tabuchi N, de Haan J, van Oeveren W. Rapid recoveryof platelet function after cardiopulmonary bypass. Blood 1993; 82: 2930-1.
21. Zimmermann N, Wenk A, Kim U, Kienzle P, Weber AA, et al. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation 2003; 108: 542-7.
22. Ikeda Y, Kikuchi M, Murakami H, Satoh K, MurataM, et al. Comparison of the inhibitory effects of cilostazol, acetylsalicylic acid and ticlopidine on platelet functions ex vivo. Randomized, double-blindcross-over study. Arzneimittelforschung 1987; 37: 563-6.
23. Minami N, Suzuki Y, Yamamoto M, Kihira H, Imai E, et al. Inhibition of shear stress-induced platelet aggregation by cilostazol, a specific inhibitor of cGMPinhibited phosphodiesterase, in vitro and ex vivo. Life Sci 1997; 61: PL383-9.
24. Takahashi S, Oida K, Fujiwara R, Maeda H, Hayashi S, et al. Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture. J Cardiovasc Pharmacol 1992; 20: 900-6.
25. Takai S, Jin D, Nishimoto M, Sakaguchi M, Kirimura K, et al. Cilostazol suppresses intimal formation in dog grafted veins with reduction of angiotensin IIforming enzymes. Eur J Pharmacol 2001; 411: 301-4.